The Association of A/G Polymorphism in Intronic Region of FGFR2 Gene and Breast Cancer

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Biology, School of Sciences, University of Isfahan, Isfahan, Iran

2 MSc Student, Department of Biology, School of Sciences, University of Isfahan, Isfahan, Iran

Abstract

Background: Fibroblast growth factor receptor 2 (FGFR2) is a receptor of tyrosine kinase with a pivotal role in the cell growth and differentiation. FGFR2 gene was identified as susceptibility gene for breast cancer by Genome-wide associated study. rs1219648 polymorphisms in intronic region are associated with breast cancer. FGFR2 gene is amplified in 15-10% of breast tumors. Single-nucleotide polymorphisms (SNPs) of this region are involved in FGFR2 amplification. In this study, the association of rs1219648 in intron 2 region of FGFR2 gene and breast cancer was assessed.Methods: In the present study, 80 cases of breast cancer and 100 healthy controls were studied. After DNA extraction from blood, specific sequence was amplified by tetra primer ARMS-PCR (amplification-refractory mutation system-polymerase chain reaction) technique and genotype of C/T polymorphism was determined by agarose gel electrophoresis.Findings: Individuals with G/G and A/G genotype were at a significantly higher risk of breast cancer (OR = 5.32, P = 0.018). G allele frequency in case patients were greater than controls but this increase did not show significant relationship with breast cancer (P = 0.230).Conclusion: Single nucleotide polymorphism of G/A in intron 2 of the FGFR2 tyrosine kinase receptor gene may play a role as a risk factor for breast cancer susceptibility.

Keywords

References

  1. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003; 53(6): 342-55.
  2. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83(4): 803-19.
  3. Yavari P, Mosavizadeh M, Sadrol-Hefazi B, Mehrabi Y. Reproductive characteristics and the risk of breast cancer--a case-control study in Iran. Asian Pac J Cancer Prev 2005; 6(3): 370-5.
  4. Tenhagen M, van Diest PJ, Ivanova IA, van der Wall E, van der Groep P. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer 2012; 19(4): R115-R129.
  5. McLeskey SW, Ding IY, Lippman ME, Kern FG. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res 1994; 54(2): 523-30.
  6. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000; 22(2): 108-12.
  7. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437(2): 199-213.
  8. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007; 67(11): 5461-70.
  9. Martin AJ, Grant A, Ashfield AM, Palmer CN, Baker L, Quinlan PR, et al. FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes 2011; 4: 72.
  10. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10(2): 116-29.
  11. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8(3): 161-73.
  12. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7(3): 165-97.
  13. Rebbeck TR, DeMichele A, Tran TV, Panossian S, Bunin GR, Troxel AB, et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis 2009; 30(2): 269-74.
  14. Tannheimer SL, Rehemtulla A, Ethier SP. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000; 2(4): 311-20.
  15. Raskin L, Pinchev M, Arad C, Lejbkowicz F, Tamir A, Rennert HS, et al. FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev 2008; 17(5): 1060-5.
  16. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39(7): 870-4.
  17. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447(7148): 1087-93.
  18. Sun C, Olopade OI, Di RA. rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet 2010; 197(2): 193-4.
  19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3): 1215.
  20. Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, et al. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008; 29(12): 2341-6.
  21. Zhang J, Qiu LX, Wang ZH, Leaw SJ, Wang BY, Wang JL, et al. Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010; 124(2): 419-24.
  22. Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008; 6(5): e108.
Journal of Isfahan Medical School
Volume 32, Issue 279 - Serial Number 279
January and February 2014
Pages 359-367

Files

History

  • Receive Date: 18 December 2013
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics